Marinus Pharma (MRNS) Reports In-Line Q4 EPS

Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Citizens launches transportation coverage, names FedEx a top large-cap pick
• Jewett-Cameron Trading Company Ltd. (JCTC) Reports Q3 Loss of $0.23
• Morgan Stanley Resumes Rakuten Bank Ltd (5838:JP) at Equalweight